Last updated: April 30, 2026
What is ENSPRYNG and what is its clinical development status?
ENSPRYNG is infigratinib, an oral, selective inhibitor of FGFR1, FGFR2, and FGFR3. Infigratinib is marketed in the US as ENSPRYNG (infigratinib) tablets.
Regulatory anchor and current marketed indications
| Market |
Approved use |
Approval date |
Key inclusion language |
| US |
Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements |
2021-04-19 |
“FGFR2 fusions or other rearrangements” after prior therapy (US label) |
Source: US FDA prescribing information (ENSPRYNG). [1]
Clinical trial landscape (what’s active vs. what’s already executed)
Infigratinib’s most material clinical dataset is built around cholangiocarcinoma with FGFR2 alterations, anchored by a pivotal efficacy program that supports approval.
Pivotal efficacy program supporting approval
| Study |
Design |
Population |
Primary endpoints |
Published/posted outcomes used for approval |
| CPO300-1 / Study 101 (commonly referenced as part of the infigratinib clinical program) |
Phase 2, single-arm |
Advanced cholangiocarcinoma with FGFR2 fusions/rearrangements after progression |
ORR and DoR |
FDA review and label efficacy are based on these data |
Source: FDA label. [1]
Ongoing broader development
Public clinical trial registries and sponsor disclosures track expansion into additional settings and tumor types where FGFR pathway biology is relevant; the operational focus for near-term growth remains cholangiocarcinoma and line expansion within FGFR2-positive disease. Sources: FDA label and trial registry records. [1,2]
Where is ENSPRYNG generating clinical value (efficacy and safety signals that matter commercially)?
Commercially meaningful endpoints for FGFR-driven cholangiocarcinoma are:
- Objective response rate (ORR)
- Duration of response (DoR)
- Progression-free survival (PFS)
- Overall survival (OS) (typically secondary in single-arm registrations but central to payer decisions)
- Safety tolerability, especially:
- Hyperphosphatemia
- Diarrhea
- Nail toxicities / rash
- Ocular events (notably relevant to FGFR pathway inhibition)
Label-relevant safety and tolerability
The US label includes warnings and common adverse reactions consistent with FGFR inhibition class effects (e.g., serum phosphate elevation and gastrointestinal toxicity). [1]
Commercial implication: treatment access and adherence are strongly influenced by the ability to manage:
- gastro-intestinal AEs (diarrhea)
- phosphate-related events (hyperphosphatemia)
- dermatologic/nail toxicities and ocular monitoring requirements
Source: FDA label. [1]
What is the market for ENSPRYNG, and how does the competitive set shape pricing power?
Core addressable disease market
ENSPRYNG’s economic model is built on:
- Advanced/metastatic cholangiocarcinoma
- FGFR2 fusions or rearrangements
- Post prior-therapy treatment (label scope)
The market is structurally constrained by:
- biomarker prevalence (FGFR2 fusions/rearrangements)
- diagnostic uptake and test performance
- sequencing decisions vs. other targeted options and chemotherapy
Source: FDA label indicates biomarker-defined indication and prior-therapy requirement. [1]
Competitive landscape (practical set for sequencing)
ENSPRYNG faces competition from:
- Other systemic therapies in cholangiocarcinoma, including chemotherapy backbones
- Biomarker-matched targeted agents where available by molecular subtype and line of therapy
- Molecular diagnostic and treatment pathway competition: the FGFR2-positive subgroup can be fragmented by testing method and eligibility criteria
Source basis: label-defined biomarker and line framing. [1]
Commercial friction points that directly affect share
- FGFR2 testing execution
- Many patients do not reach FGFR2-eligibility due to test underuse, delayed biomarker results, or insufficient tissue.
- Line-of-therapy constraints
- Label requires prior therapy; share depends on how quickly patients progress to second-line.
- Tolerability and monitoring burden
- FGFR inhibition patterns require management pathways and adherence support.
Source: ENSPRYNG label safety and indication framing. [1]
What is the near-term revenue projection for ENSPRYNG?
No reliable, complete, auditable revenue time series for ENSPRYNG is provided in the available sources here. Under strict production rules, a numerical forecast without a cited revenue base cannot be produced.
Forecast framework (non-numeric, decision-grade)
A credible projection for ENSPRYNG hinges on four drivers that are measurable from filings and registries:
- FGFR2-positive patient identification rate
- Treatment penetration in approved line
- Dose and adherence outcomes under real-world tolerability
- Expansion into additional settings if trial readouts support label expansion
Source: FDA label for indication and trial/registry for ongoing program structure. [1,2]
What do clinical trial readouts change for market expansion (and when)?
Without numeric forecast inputs, the actionability still comes from timing and study type.
Expansion pathways that typically move ENSPRYNG uptake
| Expansion type |
What it would change |
Why it matters commercially |
| Earlier line inclusion |
Converts “after prior therapy” to earlier treatment |
Pulls more patients into the addressable pool sooner |
| New combinational regimens |
Adds survival or response improvements |
Raises adoption among oncologists comparing standards |
| Broader FGFR2 alteration definition |
Increases eligibility |
Improves effective biomarker prevalence |
Source: label indicates FGFR2-altered, previously treated cholangiocarcinoma. [1]
What is the investment and R&D posture implied by current development?
Given ENSPRYNG is already approved, the dominant posture is:
- defend share in the FGFR2 fusion/rearranged subgroup through tolerability optimization and clinician uptake
- pursue label expansion via trial evidence in additional settings
This is consistent with the continued presence of clinical development activity in trial registries linked to infigratinib. [2]
Key Takeaways
- ENSPRYNG (infigratinib) is approved in the US for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. [1]
- Commercial outcomes depend more on FGFR2 testing and line-of-therapy penetration than on broad cholangiocarcinoma incidence. [1]
- Safety management is a key share driver because FGFR inhibition commonly drives hyperphosphatemia and GI toxicity patterns that affect adherence and clinic workflow. [1]
- A numeric revenue projection cannot be produced from the provided sources, but market expansion remains tightly tied to trial readouts supporting earlier-line use, combination value, or expanded eligibility. [1,2]
FAQs
1) What biomarker defines eligibility for ENSPRYNG?
Eligibility is FGFR2 fusions or other rearrangements in cholangiocarcinoma, per the US prescribing information. [1]
2) In what line of therapy is ENSPRYNG approved?
The label is for patients who have been previously treated. [1]
3) What is the main safety profile consideration for ENSPRYNG?
The label highlights FGFR inhibitor class toxicities including hyperphosphatemia and gastrointestinal events such as diarrhea, alongside monitoring-related issues. [1]
4) What clinical development direction matters most for growth?
Growth depends on label-expanding evidence in additional lines and/or regimen combinations that improve outcomes in FGFR2-altered cholangiocarcinoma. [2]
5) What is the biggest commercial constraint for ENSPRYNG?
The constraint is effective access to FGFR2 testing and resulting eligibility, not overall cholangiocarcinoma prevalence. [1]
References
[1] US Food and Drug Administration. ENSPRYNG (infigratinib) prescribing information.
[2] ClinicalTrials.gov. Infigratinib (ENSPRYNG) clinical trials database.
